Kezar Life Sciences (NASDAQ:KZR) Earns Outperform Rating from William Blair

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “outperform” rating reiterated by William Blair in a note issued to investors on Friday,RTT News reports.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd. Wells Fargo & Company dropped their target price on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, December 19th.

Kezar Life Sciences Price Performance

NASDAQ:KZR traded down $0.24 on Friday, hitting $5.66. The company had a trading volume of 17,310 shares, compared to its average volume of 31,868. Kezar Life Sciences has a 52 week low of $5.20 and a 52 week high of $11.35. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $41.26 million, a price-to-earnings ratio of -0.43 and a beta of 0.19. The firm has a 50 day moving average of $6.35 and a two-hundred day moving average of $6.73.

Hedge Funds Weigh In On Kezar Life Sciences

Hedge funds have recently modified their holdings of the business. Stonepine Capital Management LLC raised its position in Kezar Life Sciences by 42.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock worth $1,153,000 after purchasing an additional 440,853 shares during the last quarter. Ikarian Capital LLC increased its stake in shares of Kezar Life Sciences by 23.0% in the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock valued at $827,000 after buying an additional 200,000 shares during the period. Geode Capital Management LLC raised its position in shares of Kezar Life Sciences by 15.0% during the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after acquiring an additional 81,678 shares during the last quarter. Peapod Lane Capital LLC acquired a new position in shares of Kezar Life Sciences in the fourth quarter worth approximately $833,000. Finally, Shay Capital LLC bought a new stake in Kezar Life Sciences in the fourth quarter valued at approximately $398,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.